Established in the early 90’s SCL offers a wide range of Active Pharmaceutical Ingredients and Intermediates to its customers worldwide. SCL’s products are exported to Europe, Japan, Russia, South and Central America, ASEAN, W.Asia, MENA regions. Amongst our international customers are : Sanofi Aventis, DSM, Sandoz, Stada, Eisai, Actavis, Lonza, Krka, A.E.Tieffeubacher etc. while our domestic customers include major pharmaceutical companies such as Lupin, Ranbaxy, Hospira(ex-Orchid) and Aurobindo Pharma.
SCL’s manufacturing facilities have been built to comply with EU GMP and U.S. FDA norms, and the API facility has been successfully certified as EU GMP compliant five times by the European Authorities. Latest certification was carried out by German Health Authority, Berlin in AUG-2012. Besides manufacturing, SCL also operates a pharmaceuticals trading and distribution business offering Generic Finished Dosages and Pharmaceutical Ingredients. Our participation in areas across the pharmaceuticals industry ensures firsthand, leading-edge knowledge and bolsters our strength as a partner to customers and suppliers alike.
In early 2013, Mitsubishi Corporation, Japan became a Partner in SCL by acquiring an Equity stake in the Shareholding of SCL. This partnership is expected to bring huge advantage to SCL through access to the Japanese market as well as in different parts of the world through MC’s wide spread distribution network.
Our main Business Areas are:
- Manufacturing of Bulk APIs and Intermediates
- Custom Manufacturing and Custom synthesis
- Trading in APIs, Pharmaceutical Intermediates, Finished Dosages.